Zobrazeno 1 - 3
of 3
pro vyhledávání: '"35"'
Autor:
Kate Fitch, Scott C. Flanders, Michael T. Schweizer, Rana R. McKay, Christine Ferro, Michael D. Fabrizio
Publikováno v:
Journal of Clinical Oncology. 38:42-42
42 Background: Since the mCRPC treatment landscape is evolving, we examined real-world use and outcomes of sipuleucel-T (sip-T) and oral agents (abiraterone acetate and enzalutamide) in men with mCRPC. Methods: Using Medicare FFS Identifiable Researc
Autor:
Nina Tunariu, Roberto Alonzi, Holly Tovey, John Staffurth, Helen Stidwill, Matthew D. Blackledge, Alison Tree, Chris Parker, Sophie Perry, Emma Hall, Dow-Mu Koh, Anwar R. Padhani, Peter Chatfield, Jessica Finch
Publikováno v:
Journal of Clinical Oncology. 37:e16513-e16513
e16513 Background: Ra-223 improves overall survival in patients with mCRPC, but is associated with increased risk of fracture when used in combination with abiraterone and prednisolone. We have assessed time to first new fracture in men with mCRPC re
Autor:
Carlos López-López, Masatoshi Kudo, Soamnauth Misir, Angel Alsina, Ann-Lii Cheng, Arndt Vogel, T.R. Jeffry Evans, Richard S. Finn, Shukui Qin, Min Ren, Bruno Daniele, Namiki Izumi, Baek-Yeol Ryoo, Won Young Tak
Publikováno v:
Journal of Clinical Oncology. 37:371-371
371 Background: Lenvatinib (LEN) was shown to be noninferior to sorafenib (SOR) for overall survival (OS) in REFLECT (median OS [mOS], 13.6 vs 12.3 months [mo]; HR 0.92; 95% CI 0.79–1.06). LEN was superior vs SOR for secondary endpoints including o